EUCTR2004-001044-72-IT进行中（未招募）不适用
Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
AVENTIS PHARMA S.P.A.0 个研究点目标入组 84 人开始时间: 2007年1月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A randomised phase II study evaluating two schedules of the 21-day regimen of Gemcitabine and Carboplatin in advanced NSCLCon-small cell lung cancerEUCTR2006-000744-17-BEniversity Hospital Ghent64
进行中（未招募）
不适用
randomized phase II trial of two different sequences in first line chemotherapy of advanced non small cell lung cancer - NDnon small cell lung cancerMedDRA version: 9.1Level: PTClassification code 10062042MedDRA version: 9.1Level: SOCClassification code 10029104EUCTR2008-005967-33-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
尚未招募
2 期
A clinical Trial Comparing instillation of Single dose Gemcitabine versus Mitomycin-C in urinary bladder after Complete Resection of urinary bladder cancerCTRI/2020/08/027068AIIMS
进行中（未招募）
1 期
Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumabnon-small-cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001713-37-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)176
进行中（未招募）
不适用
Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck. - ICRATPatients with histologically proven unresectable squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx (stage IVa & IVb).EUCTR2010-019347-18-DECharité - Universitätsmedizin Berlin